Clinical Trials in New York

Showing 8141-8160 of 17,259 trials

A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT03650491

This study will test the safety and efficacy of FOR46 given every 21 days to patients with relapsed or refractory multiple myeloma. The name of the study drug involved in this study is: FOR46 for Injection

Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma With Failed Remission

Fortis Therapeutics, Inc.31 participantsStarted Apr 2019

San Francisco, California, United States • Aurora, Colorado, United States • Atlanta, Georgia, United States +4 more locations

COMPLETEDPhase 2< 1 mile

Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

NCT03315130

The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with generalized Myasthenia Gravis (gMG). Subjects will be randomized in a 1:1:1 ratio to receive daily SC doses of 0.1 mg/kg RA101495, 0.3 mg/kg RA101495, or matching placebo for 12 weeks.

Generalized Myasthenia Gravis

Ra Pharmaceuticals45 participantsStarted Oct 2017

Mobile, Alabama, United States • Carlsbad, California, United States • Los Angeles, California, United States +27 more locations

A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

Find Trials by Condition in New York

Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy

A Study of Immune Responses to the Virus That Causes COVID-19

Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms

A Study of PLX2853 in Advanced Malignancies.

Narrative or Fact-Based Videos in Increasing Colorectal Cancer Screenings in African American Communities

Evaluating the Effectiveness of the Safe at Home Program

Augmented Reality Mobile Application for Glaucoma Education in the South Bronx

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis